antibody

Anti-ERCC1 [8F1] NEW

153782

monoclonal

mouse

nonconjugated

2067

human, rat

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, FACS

153782

FACS IHC IF IP WB

ERCC1

ERCC Excision Repair 1, Endonuclease Non-Catalytic Subunit, Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 1 (Includes Overlapping Antisense Sequence), Excision Repair Cross-Complementation Group 1, DNA Excision Repair Protein ERCC-1, COFS4, RAD10, UV20

Human and Rat

The mammalian ERCC1 (Excision Repair Cross Complementing) polypeptide is required for nucleotide excision repair (NER) of damaged DNA and is homologous to Saccharomyces cerevisiae RAD10, which functions in repair and mitotic intrachromosomal recombination. NER mechanism involves dual incisions on both sides of the damage catalyzed by two nucleases. In mammalian cells XPG cleaves 3' of the DNA lesion while the ERCC1-XPF complex makes the 5' incision. Elevated levels of ERCC1 have been reported in Cisplatin-resistant cells. Defects in ERCC1 are the cause of cerebro-oculo-facio-skeletal syndrome type 4 (COFS4) [MIM:610758]. COFS is a degenerative autosomal recessive disorder of prenatal onset affecting the brain, eye and spinal cord. After birth, it leads to brain atrophy, hypoplasia of the corpus callosum, hypotonia, cataracts, microcornea, optic atrophy, progressive joint contractures and growth failure. Facial dysmorphism is a constant feature. Abnormalities of the skull, eyes, limbs, heart and kidney also occur.

Mouse

Full length, HIS-tagged recombinant Human ERCC1

IgG2b

Tonsil

36 kDa

DMEM + 5% FCS

Balb/c

Cancer, DNA Damage and Repair

Nuclear localisation